2 Stocks Taking a Gut Shot: Huntsman Corporation (HUN), ZIOPHARM Oncology, Inc. (ZIOP)

Huntsman Corporation (NYSE:HUN) recent drop took place on significantly less volume which dipped to nearly 1.78 million contracts on 03-Jan-19 versus its daily average of 3.62 million. The first sale was made at $19.68 but later the stock became weaker, and closed with a fall of -1.92%. It was last traded at $19.38 apiece.

Huntsman Corporation (HUN): Outperform Candidate With 65.27% Upside Potential

Huntsman Corporation is maintained at an average outperform rating by 15 stock analysts, and there are at least 2.04% of shares outstanding that are currently legally short sold. The shares went down by -4.15% in value last month. Year-to-date it jumped 0.47%. Analysts are turning out to be more optimistic than before, with 11 of analysts who cover Huntsman Corporation (NYSE:HUN) advice adding it to buy candidate list. Wall Street experts also assign a $32.03 price target on Huntsman Corporation, pointing towards a 65.27% rally from current levels. The stock is trading for about -46.3% less than its 52-week high.

Huntsman Corporation Reports -5.82% Sales Growth

Huntsman Corporation (HUN) remained successful in beating the consensus-estimated $0.81 as it actually earned $0.84 per share in its last reported financial results. Revenue, on the other hand, scored -5.82% growth from the previous quarter, coming up with $2.26 billion.

HUN Adds 0.31% In A Week

This company shares (HUN) so far managed to recover 10.24% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 3.88% while shortening the period to a week, volatility was 4.54%. The share price has already crossed its 20 days moving average, floating at a distance of 2.54% and sits -5.09% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 0.31% gains and is down by -30% compared with its 200-day moving average of $26.24. Also, Huntsman Corporation (HUN) needs to overturn a -43.33% decrease it experienced over the past twelve months.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Consensus Call At 2.8

As regular trading ended, ZIOPHARM Oncology, Inc. (ZIOP) stock brought in a -$0.06 drop to $2.15. The day started at a price of $2.2 but then traded as high as $2.22 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2.8. ZIOPHARM Oncology, Inc. is given 0 buy-equivalent recommendations, 0 sells and 1 holds. The company shares sank -59.01% from their peak of $5.24 and now has a $350.32 million market value of equity.

ZIOPHARM Oncology, Inc. Could Grow 109.3% More

ZIOP’s mean recommendation on Reuter’s scale slipped from 3 thirty days ago to 2.75 now, which indicates a hold consensus from the analyst community. They see ZIOPHARM Oncology, Inc. (ZIOP) price hitting a mean target of $4.5 a share, meaning the stock still has potential that could lift the price another 109.3% . Also, the recent close suggests the stock is underpriced by 155.81% compared to the most bullish target.

ZIOPHARM Oncology, Inc. (ZIOP) Returns 14.97% This Year

The company had seen its current volume reaching at 1.62 million shares in the last trade. That compares with the recent volume average of 2.16 million. At the close of regular trading, its last week’s stock price volatility was 11.99% which for the month reaches 14.61%. ZIOPHARM Oncology, Inc. dipped to as low as $2.06 throughout the day and has returned 14.97% in this year. At one point in the past year, the shares traded as low as $1.56 but has recovered 37.82% since then.